Clinical trial registry record

Sirolimus Treatment in Pediatric Patients With Ataxia-Telangiectasia

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated September 15, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT07820579
Last registry update
September 15, 2026
Status
Completed
Phase
Phase 2
Sponsor
Sara Elva Espinosa Padilla, MD
Enrollment
6
Countries
Mexico
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
NA · SINGLE GROUP · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
6
Population
ALL · 16 Years
Duration
2024-07-11 to 2026-08-20
Intervention
Rapamune (sirolimus/rapamycin)
Comparator
Not reported
Outcomes measured
Adverse effects and laboratory safety after treatment — From enrollment to the end of treatment at 6 months; Neurological function assessed by the Scale for the Assessment and Rating of Ataxia — From enrollment to the end of tre…; Immunological and laboratory evaluation — From enrollment to the end of treatment at 6 months; Percentage of conjunctival vascular area — From enrollment to the end of treatment at 6 months; Image Analysis — From enrollment to the end of treatment at 6 months; Cognitive performance assessed by the Cerebellar Cognitive Affective Syndrome Scale — From enrollment to the end of tre…; Executive functioning assessed by the Behavior Rating Inventory of Executive Function, Second Edition — From enrollment…; Emotional and behavioral functioning assessed by the Child Behavior Checklist — From enrollment to the end of treatment…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Rapamycin · 100%Title contains controlled term: sirolimus. Abstract contains controlled term: sirolimus. Source terminology contains: rapamycin, sirolimus. Abstract supplies longevity context: aging. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

rapamycin
Open primary sourceExport JSON